{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-25-000029","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.313223+00:00","generated_at":"2026-05-26T02:01:37.511102+00:00","sec_items":["2.02","9.01","8.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B","bullets":["Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).","BRUKINSA global revenue Q4 $828M (+100%); full year $2.6B (+105%).","Full year 2025 revenue guidance $4.9-$5.3B; anticipate positive GAAP operating income in 2025.","GAAP operating loss narrowed to $79M in Q4 from $384M; achieved positive non-GAAP operating income of $79M.","Advanced 6 NMEs in Q4 and 13 in full year; plan to change name to BeOne Medicines Ltd., ticker ONC."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-25-000029","json":"https://secwatch.observer/filing/0001651308-25-000029.json","markdown":"https://secwatch.observer/filing/0001651308-25-000029.md","text":"https://secwatch.observer/filing/0001651308-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/0001651308-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/bgne-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:01:37.511102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}